Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29816440 | 1.00 | ALDH1A1 (0.57) | ALDH1A1KDM4EGAAHPGDPOLB | |
| Hydrochloric Acid SCHEMBL6208562 | 0.98 | ALDH1A1 (0.56) | ALDH1A1KDM4EGAAHPGDPOLB | |
| SCHEMBL28393741 | 0.87 | MAPT (0.53) | ALDH1A1KDM4EGAAHPGDPOLB | |
| SCHEMBL8048603 | 0.87 | ALDH1A1 (0.61) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2323487 | 0.85 | ALDH1A1 (0.64) | ALDH1A1KDM4EGAAHPGDPOLB | |
| SCHEMBL1286677 | 0.84 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDPOLBMAPT | |
| SCHEMBL29410870 | 0.84 | NPC1 (0.70) | ALDH1A1KDM4EGAAPOLBMAPT | |
| SCHEMBL7757288 | 0.84 | MAPT (0.50) | ALDH1A1KDM4EGAAHPGDPOLB | |
| SCHEMBL325422 | 0.84 | NPC1 (0.70) | ALDH1A1KDM4EGAAPOLBMAPT | |
| SCHEMBL6608136 | 0.84 | AKR1C3 (0.53) | ALDH1A1KDM4EGAAHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661473-A | Method for synthesizing beta-sulfur trifluoromethyl alkylamine by olefin difunctional reaction | 东北师范大学 | 2025-03-21 | — | — | CN | claimed |
| CN-118360608-B | Copper-reducing additive for IC carrier plate and preparation method and use method thereof | 深圳市板明科技股份有限公司 | 2024-08-13 | — | — | CN | claimed |
| CN-118360608-A | Copper-reducing additive for IC carrier plate and preparation method and use method thereof | 深圳市板明科技股份有限公司 | 2024-07-19 | — | — | CN | claimed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-105732889-A | Photosensitive resin and synthetic method thereof | 深圳市容大感光科技股份有限公司 | 2016-07-06 | — | — | CN | claimed |
| US-20050010045-A1 | Reacting morpholine compound with a substituted benzene compound | TIAN WEI (SE) | 2005-01-13 | — | — | US | claimed |
| US-6689882-B2 | REACTING A MORPHOLINE WITH A SUBSTITUTED BENZENE, WHEREIN MORPHOLINE IS USED AS A REACTANT AND AS THE ONLY ONE SOLVENT | ASTRAZENECA AB (SE) | 2004-02-10 | — | — | US | claimed |
| US-20030171581-A1 | Process for the synthesis of morpholinylbenzenes | ASTRAZENECA AB (SE) | 2003-09-11 | — | — | US | claimed |
| EP-1286977-A1 | A NEW PROCESS FOR THE SYNTHESIS OF MORPHOLINYLBENZENES | AstraZeneca AB (SE) | 2003-03-05 | — | — | EP | claimed |
| WO-2001087865-A1 | A NEW PROCESS FOR THE SYNTHESIS OF MORPHOLINYLBENZENES | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | claimed |
| US-20250257041-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-08-14 | — | — | US | disclosed |
| CN-120192315-A | Echinococcosis-resistant medicine and preparation method and application thereof | 新疆医科大学 | 2025-06-24 | — | — | CN | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4526291-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | The Board of Regents of the University of Texas System (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2000044730-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-6071903-A | ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-06-06 | — | — | US | disclosed |
| US-5962440-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999037625-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999021564-A1 | CYCLIC PHOSPHONATE ESTER INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257041-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | DDIT3, ATF4, EIF2AK3 | ALDH1A1 4205/4885KDM4E 3125/4885GAA 3353/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885KDM4E 1198/4885GAA 1755/4885 |
| US-20030171581-A1 | Process for the synthesis of morpholinylbenzenes | CYP1B1, TBCB, MAP1B | ALDH1A1 1548/4885KDM4E 2640/4885GAA 2462/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | ALDH1A1 4172/4885KDM4E 4059/4885GAA 1366/4885 |
| US-20050010045-A1 | Reacting morpholine compound with a substituted benzene compound | CYP1B1, MYB, MYBBP1A | ALDH1A1 1944/4885KDM4E 2799/4885GAA 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.